Fresenius SE & Co. KGaA (VIE:FRE)
Austria · Delayed Price · Currency is EUR | Market Cap | 26.43B +19.1% |
| Revenue (ttm) | 22.45B +4.5% |
| Net Income | 1.14B |
| EPS | 2.03 |
| Shares Out | n/a |
| PE Ratio | 23.12 |
| Forward PE | 12.91 |
| Dividend | 1.00 (2.14%) |
| Ex-Dividend Date | May 26, 2025 |
| Volume | n/a |
| Average Volume | 429 |
| Open | 46.83 |
| Previous Close | 46.97 |
| Day's Range | 46.83 - 46.83 |
| 52-Week Range | 35.29 - 52.76 |
| Beta | n/a |
| RSI | 40.23 |
| Earnings Date | Feb 25, 2026 |
About Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through Fresenius Kabi and Fresenius Helios segment. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The company was formerly know... [Read more]
Financial Performance
Financial StatementsNews
EQS-DD: Fresenius SE & Co. KGaA: Sara Hennicken, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 16.03.2026 / 17:10 CET/CEST The issuer is solely responsi...
Glenmark Pharmaceuticals to launch Potassium Phosphates Injection in March 2026
Glenmark Pharmaceuticals Inc., USA, is set to launch its Potassium Phosphates Injection USP in March 2026, offering single-dose vials and pharmacy bulk package vials. The product is bioequivalent to F...
EQS-DD: Fresenius SE & Co. KGaA: Michael Sen, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 06.03.2026 / 10:45 CET/CEST The issuer is solely responsi...
EQS-PVR: Fresenius SE & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Fresenius SE & Co. KGaA Fresenius SE & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe...
Fresenius SE & Co KGaA (FSNUY) Full Year 2025 Earnings Call Highlights: Strong Organic ...
Fresenius SE & Co KGaA (FSNUY) Full Year 2025 Earnings Call Highlights: Strong Organic Growth and Strategic Flexibility
Full Year 2025 Fresenius SE & Co KGaA Earnings Call Transcript
Full Year 2025 Fresenius SE & Co KGaA Earnings Call Transcript
Fresenius SE & Co. (FSNUF) Reports Strong FY Core EPS Growth
Fresenius SE & Co. (FSNUF) Reports Strong FY Core EPS Growth
Fresenius posts profit beat in first quarter, confirms outlook
German healthcare group Fresenius beat analysts' adjusted operating profit expectations for the first quarter on Wednesday, citing a strong performance at its drug making division Kabi.
Fresenius SE Raises Guidance After Strong Kabi, Helios Performances
The healthcare company lifted its full-year guidance after a robust third quarter driven by Kabi and good organic growth at Helios.
Healthcare group Fresenius tops Q4 operating profit expectations
Fresenius reported a bigger-than-expected 13% jump in fourth-quarter operating profit on Wednesday, citing good earnings development across its businesses and progress in the operational turnaround at...
Fresenius perfectly positioned to combat health inequality, says CEO
Michael Sen, CEO at Fresenius, explains what the company is doing to help close the health care gap.
Fresenius to assess whether state aid impacts bonus, dividend payouts
German healthcare group Fresenius said it was examining whether the state aid it received to help offset high energy costs at its hospitals business would bar it from making management bonus and divid...
Fresenius launches biosimilar version of AbbVie's Humira at 5% discount
The generic drug unit of Germany's Fresenius said on Monday the price for Idacio, its copycat version of Abbvie's top-selling rheumatoid arthritis drug, will be at a 5% discount to Humira's list price...
Germany's Fresenius to simplify structure, flags potential profit fall
German healthcare group Fresenius SE will slash costs and proceed with plans to cede strategic control over struggling dialysis group Fresenius Medical Care (FMC) as its new CEO seeks to simplify the ...
Fresenius SE CEO to quit after earnings outlook sours
FRANKFURT (Reuters) -Fresenius SE said its long-serving Chief Executive Stephan Sturm would quit, to be replaced by the head of its drugs unit, after the diversified group's earnings were hit followin...
Healthcare group Fresenius raises 2021 forecasts
German healthcare group Fresenius raised 2021 targets though it saw a weaker third quarter, saying progress on its cost-cutting plan should offset troubles at its dialysis unit.
Fresenius CEO says second quarter was 'very strong,' driven by hospitals business
Stephan Sturm, chief executive officer of Fresenius, discusses the firm's second-quarter earnings.